What are the guidelines for initiating antiviral therapy in a treatment‑naïve, HBsAg‑positive, HBeAg‑negative chronic hepatitis B patient with ALT 3890 U/L and low HBV DNA levels?

Immediate Antiviral Therapy Indicated

This treatment-naïve, HBeAg-negative, HBsAg-positive patient with ALT 3890 U/L (>100× ULN) requires immediate initiation of nucleos(t)ide analogue therapy regardless of HBV DNA level. 1

Treatment Rationale

The markedly elevated ALT (3890 U/L) represents severe hepatic necroinflammation and meets all guideline criteria for urgent treatment initiation:

• ALT >2× ULN with any detectable HBV DNA mandates treatment in HBeAg-negative chronic hepatitis B 1, 2
• The extremely elevated transaminases (>100× normal) indicate acute hepatic injury requiring immediate viral suppression
• Even with "low" HBV DNA levels mentioned, the severe biochemical flare supersedes DNA thresholds as the primary treatment trigger

First-Line Treatment Selection

Initiate entecavir OR tenofovir (TAF or TDF) immediately 1:

• These are the only recommended first-line nucleos(t)ide analogues with high barrier to resistance
• Entecavir: 0.5 mg daily (treatment-naïve patients)
• Tenofovir alafenamide (TAF): 25 mg daily (preferred if renal/bone concerns)
• Tenofovir disoproxil fumarate (TDF): 300 mg daily

Do NOT use lamivudine or adefovir - these have unacceptably high resistance rates and are no longer recommended 1

Critical Management Points

Immediate Actions:

• Start antiviral therapy today - do not wait for additional testing or liver biopsy
• Assess for signs of hepatic decompensation (INR, albumin, bilirubin, platelets)
• Rule out acute liver failure (encephalopathy, coagulopathy)
• Check for co-infections (HIV, HCV, HDV) that might alter management

No Liver Biopsy Required:

The ALT elevation of this magnitude with positive HBsAg establishes the diagnosis and treatment indication without histological confirmation 2, 3

Treatment Duration

This patient requires indefinite/lifelong therapy because:

• HBeAg-negative chronic hepatitis B rarely achieves durable off-treatment response
• Treatment can only be considered for discontinuation after HBsAg loss confirmed on two occasions 6 months apart 1
• Even then, stopping requires: no advanced liver disease, low HBsAg levels (<1,000 IU/mL for Caucasians, <100 IU/mL for Asians), and at least 12 months consolidation therapy after HBsAg loss 1

Monitoring Protocol

First 6 Months (Monthly):

• ALT, AST
• HBV DNA (expect suppression to <100 IU/mL by 6-12 months)
• Complete blood count, creatinine

After 6 Months (Every 3 months):

• ALT, HBV DNA
• HBsAg quantification every 6-12 months
• Renal function and bone density monitoring if on TDF

Hepatocellular Carcinoma Surveillance:

• Ultrasound + AFP every 6 months lifelong 4
• This patient's severe hepatitis increases cirrhosis/HCC risk even after viral suppression

Common Pitfalls to Avoid

1. Do not delay treatment waiting for HBV DNA results or repeat ALT - the current ALT elevation is sufficient
2. Do not use suboptimal agents (lamivudine, adefovir, telbivudine) - resistance rates are prohibitive
3. Do not stop therapy prematurely - HBeAg-negative patients require treatment until HBsAg loss, which occurs in <10-15% over 5-6 years 1
4. Do not assume "low DNA" means mild disease - this patient's ALT demonstrates severe active hepatitis requiring treatment regardless of viral load 5

The 2025 EASL guidelines 1 and supporting evidence 5 confirm that treatment decisions in HBeAg-negative disease prioritize ALT elevation and liver injury over absolute HBV DNA thresholds, particularly when ALT exceeds 2× ULN.